Ionis Pharmaceuticals’s Earnings Outlook

Ionis Pharmaceuticals (NASDAQ:IONS) is set to give its latest quarterly earnings report on Wednesday, 2023-02-22. Here’s what investors…

Ionis Pharmaceuticals (NASDAQ:IONS) is set to give its latest quarterly earnings report on Wednesday, 2023-02-22. Here’s what investors need to know before the announcement.

Analysts estimate that Ionis Pharmaceuticals will report an earnings per share (EPS) of $-0.92.

Ionis Pharmaceuticals bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company beat EPS by $0.58, which was followed by a 5.6% increase in the share price the next day.

Here’s a look at Ionis Pharmaceuticals’s past performance and the resulting price change:

Quarter Q3 2022 Q2 2022 Q1 2022 Q4 2021
EPS Estimate -0.74 -0.62 -0.71 0.28
EPS Actual -0.16 -0.56 -0.27 1.55
Price Change % 5.6% 4.18% -3.87% -2.19%

eps graph

Stock Performance

Shares of Ionis Pharmaceuticals were trading at $38.6 as of February 20. Over the last 52-week period, shares are up 25.48%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

To track all earnings releases for Ionis Pharmaceuticals visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Decibel Cannabis Reports 16% YoY Drop In Q1 Revenue, CEO Expects Improved Q2 And ‘Continued Path To Sustainable Growth And Profitability’

Decibel Cannabis Company Inc. (TSXV: DB) (OTCQB: DBCCF), a maker of premium cannabis and extract manufactured products, announced on Wednesday its unaudited interim financial results for the three months ending March 31, 2024. The Calgary, Alberta-based company reported a year-over-year decrease of 16% in net revenue to $21 million. Benjamin Sze, the company's CEO said that "despite the drop in revenue, we remain one of Canada's top brands by market share." The company boasted a national market share of 6% in the first quarter, placing it as the 4th largest licensed producer in Canada by market share, the company said in a press release.

DB